MINI-FUTURE SHORT - ELI LILLY & CO | Market Closed - Swiss Exchange 16:20:00 27/05/2024 BST | ||
| 0.47 CHF | -2.08% |
|
| Current month | -60.50% | ||
| 1 month | -60.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 27/05/24 | 0.47 | -2.08% |
| 24/05/24 | 0.48 | +4.35% |
| 23/05/24 | 0.46 | -17.86% |
| 22/05/24 | 0.56 | +5.66% |
Delayed Quote Swiss Exchange
Last update May 27, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYG7U | |
| ISIN | CH1322971297 |
| Date issued | 07/02/2024 |
| Strike | 859.3 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 1.35 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.27 CHF |
|---|---|
| Lowest since issue | 0.46 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.96% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
- Stock Market
- Certificates
- LLYG7U Certificat
